In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 1 to 25 of 381

Sort by

Type: Guidance`Remove $Type: Guidance filter`
Type: Quality standard`Remove $Type: Quality standard filter`
Type: NICE advice`Remove $Type: NICE advice filter`

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
12 SQ-HDM SLIT for treating allergic rhinitis caused by house dust mites in children 5 to 11 years [ID6510]	Technology appraisal guidance	26 August 2026
Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059]	Technology appraisal guidance	TBC
Abemaciclib with fulvestrant for previously treated hormone receptor-positive HER2-negative advanced breast cancer [TSID12065]	Technology appraisal guidance	TBC
Abicipar pegol for treating wet age-related macular degeneration [ID1533]	Technology appraisal guidance	TBC
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]	Technology appraisal guidance	19 August 2026
Acalabrutinib with venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia [ID6232]	Technology appraisal guidance	19 August 2026
Aggressive behaviour in people receiving NHS or social care	Quality standard	28 January 2027
Aggressive behaviour in people receiving NHS or social care: prevention and management	NICE guideline	28 January 2027
Alcohol Use Disorders (update)	NICE guideline	TBC
ALXN1840 for treating Wilson disease [ID6422]	Technology appraisal guidance	TBC
Anitocabtagene autoleucel for treating relapsed or refractory multiple myeloma ID6549	Technology appraisal guidance	20 May 2027
Apadamtase alfa for treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192]	Technology appraisal guidance	TBC
Arimoclomol for treating Niemann-Pick disease Type C [ID1312]	Highly specialised technology	TBC
Artificial intelligence (AI) technologies to assist histopathology for breast cancer diagnosis [ID6732]	Technology appraisal guidance	17 June 2027
Artificial intelligence (AI) technologies to assist histopathology for prostate cancer diagnosis [ID6684]	Technology appraisal guidance	21 April 2027
Artificial intelligence (AI) technologies to help detect prostate cancer on MRI	HealthTech guidance	12 November 2026
Artificial intelligence-assisted software to aid polysomnography scoring in sleep disorder diagnosis	HealthTech guidance	21 April 2027
Astegolimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6524]	Technology appraisal guidance	TBC
Asunercept for treating glioblastoma [ID1301]	Technology appraisal guidance	TBC
Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer [TSID10701]	Technology appraisal guidance	TBC
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID3894]	Technology appraisal guidance	TBC
Atezolizumab for adjuvant treatment of circulating tumour DNA-positive high-risk muscle-invasive bladder cancer after cystectomy [ID6515]	Technology appraisal guidance	TBC
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]	Technology appraisal guidance	TBC
Atezolizumab with BCG before surgery (neoadjuvant) for treating non-muscle-invasive bladder cancer [ID6667]	Technology appraisal guidance	TBC
Atezolizumab with chemotherapy for adjuvant treatment of stage 3 colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID6646]	Technology appraisal guidance	30 June 2027

Results per page

10
25
50
All